Dick, Stèfanie http://orcid.org/0000-0001-5548-4557
Vink, Frederique J. http://orcid.org/0000-0002-4951-9167
Heideman, Daniëlle A. M. http://orcid.org/0000-0001-6463-7391
Lissenberg-Witte, Birgit I. http://orcid.org/0000-0001-9448-1826
Meijer, Chris J. L. M. http://orcid.org/0000-0002-2758-9463
Berkhof, Johannes http://orcid.org/0000-0003-2094-2380
Article History
Received: 8 April 2021
Revised: 14 October 2021
Accepted: 21 October 2021
First Online: 6 November 2021
Ethics approval and consent to participate
: The VUSA-Screen trial was approved by the Ministry of Public Health (2002/02-WBO; ISBN-10: 90-5549-452-6) and registered in the trial register (NTR215, ISRCTN64621295). The POBASCAM trial was approved by the Medical Ethics Committee of the VU University Medical Center (no 96/103A) and by the Ministry of Public Health (VWS no 328 650) and registered in the trial register (NTR218; ISRCTN20781131). All participants provided written informed consent. The work in this study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: CJLMM and DAMH are minority stockholders of Self-screen BV, a spin-off company of VUmc, which develops, manufactures and licences the high-risk HPV assay and methylation marker assays for cervical cancer screening and holds patents on these tests. CJLMM is part-time director of Self-screen BV. He has been on the speakers bureau and served occasionally on the scientific advisory board (expert meeting) of GSK, QIAGEN, SPMSD/Merck. He has been co-investigator on a SPMSD sponsored trial, of which his institute received research funding. CJLMM has a very small number of shares of MDxHealth and previously had shares of QIAGEN. DAMH has been on the speaker’s bureau of QIAGEN and serves occasionally on the scientific advisory boards of Pfizer and Bristol-Myers Squibb. SD, FJV, BLW and JB have no competing interests.